Genmab — April 2019
-
Celebrating 20 Years http://www.genmab.com/careers/celebrating-20-years
-
the Technology appraisal guidance [by NICE was published , where you can see how they got to their decision in plain language https://www.nice.org.uk/guidance/ta573/chapter/Recommendations
-
Amgen is still working on this Anti-CD38/CD3 Bispecific T Cell-Recruiting Antibody ( https://www.ncbi.nlm.nih.gov/pubmed/30918018 ) ; just out of
interest, does anyone know if Genmab would still be allowed to work on duo or hexa bodies including CD38? or is this excluded via the JNJ dara deal? -
I think Jan have been asked these kind of questions before - and his answer was that ADC is not the way forward and when you something that works that well as dara does its better to go after other targets........and thats what Janssen does. So I dont think its relevant
-
Im sure they cant use dara for that - and dara was a quite unique antibody found among 70 or 90 antibodies they maked against CD38. So the problem would also be that they probably should use an less optimal antibody and then you behind from the beginning.
-
Billig Revlimid i US allerede fra marts 2022 ? https://www.alvogen.com/newsroom/alvogen-settles-u-s-revlimid-r-patent-litigation-with-celgene
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind